Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Medtronic
Merck
Boehringer Ingelheim
Baxter
Colorcon
Harvard Business School

Last Updated: August 15, 2022

VIEKIRA PAK (COPACKAGED) Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


When do Viekira Pak (copackaged) patents expire, and when can generic versions of Viekira Pak (copackaged) launch?

Viekira Pak (copackaged) is a drug marketed by Abbvie Inc and is included in one NDA. There are seventeen patents protecting this drug.

This drug has six hundred and sixteen patent family members in fifty-three countries.

The generic ingredient in VIEKIRA PAK (COPACKAGED) is dasabuvir sodium; ombitasvir, paritaprevir, ritonavir. One supplier is listed for this compound. Additional details are available on the dasabuvir sodium; ombitasvir, paritaprevir, ritonavir profile page.

DrugPatentWatch® Generic Entry Outlook for Viekira Pak (copackaged)

Viekira Pak (copackaged) was eligible for patent challenges on December 19, 2018.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 18, 2033. This may change due to patent challenges or generic licensing.

There have been twenty patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

< Available with Subscription >

  Try it Free

Drug patent expirations by year for VIEKIRA PAK (COPACKAGED)
DrugPatentWatch® Estimated Generic Entry Opportunity Date for VIEKIRA PAK (COPACKAGED)
Generic Entry Date for VIEKIRA PAK (COPACKAGED)*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET, TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for VIEKIRA PAK (COPACKAGED)

VIEKIRA PAK (COPACKAGED) is protected by seventeen US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of VIEKIRA PAK (COPACKAGED) is See Plans and Pricing.

This potential generic entry date is based on patent See Plans and Pricing.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting VIEKIRA PAK (COPACKAGED)

Formulations of pyrimidinedione derivative compounds
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF HCV INFECTION USING DASABUVIR

Anti-infective agents and uses thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: USE OF DASABUVIR TO INHIBIT VIRAL REPLICATION FOR THE TREATMENT OF HCV INFECTION.

Solid pharmaceutical dosage form
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Solid pharmaceutical dosage form
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Macrocyclic hepatitis C serine protease inhibitors
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Methods for treating HCV
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR WITH RIBAVIRIN.

Methods for treating HCV
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR, WITHOUT RIBAVIRIN

Anti-infective agents and uses thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: USE OF DASABUVIR TO INHIBIT VIRAL REPLICATION FOR THE TREATMENT OF HCV INFECTION.

Macrocyclic hepatitis C serine protease inhibitors
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF HCV INFECTION USING PARITAPREVIR

Methods for treating HCV
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR WITH RIBAVIRIN.

Methods for treating HCV
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR, WITHOUT RIBAVIRIN

Solid compositions
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Anti-viral compounds
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Anti-viral compounds
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF HCV INFECTION USING OMBITASVIR

Compositions and methods for treating HCV
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF HCV INFECTION USING PARITAPREVIR

Anti-infective agents and uses thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF HCV INFECTION USING DASABUVIR

Formulations of pyrimidinedione derivative compounds
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF HCV INFECTION USING DASABUVIR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie Inc VIEKIRA PAK (COPACKAGED) dasabuvir sodium; ombitasvir, paritaprevir, ritonavir TABLET;ORAL 206619-001 Dec 19, 2014 DISCN Yes No See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Abbvie Inc VIEKIRA PAK (COPACKAGED) dasabuvir sodium; ombitasvir, paritaprevir, ritonavir TABLET;ORAL 206619-001 Dec 19, 2014 DISCN Yes No See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Abbvie Inc VIEKIRA PAK (COPACKAGED) dasabuvir sodium; ombitasvir, paritaprevir, ritonavir TABLET;ORAL 206619-001 Dec 19, 2014 DISCN Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Abbvie Inc VIEKIRA PAK (COPACKAGED) dasabuvir sodium; ombitasvir, paritaprevir, ritonavir TABLET;ORAL 206619-001 Dec 19, 2014 DISCN Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Abbvie Inc VIEKIRA PAK (COPACKAGED) dasabuvir sodium; ombitasvir, paritaprevir, ritonavir TABLET;ORAL 206619-001 Dec 19, 2014 DISCN Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for VIEKIRA PAK (COPACKAGED)

International Patents for VIEKIRA PAK (COPACKAGED)

When does loss-of-exclusivity occur for VIEKIRA PAK (COPACKAGED)?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 13330993
Estimated Expiration: See Plans and Pricing

Brazil

Patent: 2015008927
Estimated Expiration: See Plans and Pricing

Canada

Patent: 88883
Estimated Expiration: See Plans and Pricing

China

Patent: 4853752
Estimated Expiration: See Plans and Pricing

Patent: 9260207
Estimated Expiration: See Plans and Pricing

Eurasian Patent Organization

Patent: 8481
Estimated Expiration: See Plans and Pricing

Patent: 2913
Estimated Expiration: See Plans and Pricing

Patent: 1590752
Estimated Expiration: See Plans and Pricing

Patent: 1791354
Estimated Expiration: See Plans and Pricing

European Patent Office

Patent: 08808
Estimated Expiration: See Plans and Pricing

Japan

Patent: 66635
Estimated Expiration: See Plans and Pricing

Patent: 15534985
Estimated Expiration: See Plans and Pricing

Patent: 18065858
Estimated Expiration: See Plans and Pricing

Mexico

Patent: 15004973
Estimated Expiration: See Plans and Pricing

Singapore

Patent: 201503051Q
Estimated Expiration: See Plans and Pricing

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering VIEKIRA PAK (COPACKAGED) around the world.

Country Patent Number Title Estimated Expiration
United Kingdom 201408665 See Plans and Pricing
Poland 2206500 See Plans and Pricing
Australia 2010258769 Anti-viral compounds to treat HCV infection See Plans and Pricing
South Korea 20140143152 ANTI-VIRAL COMPOUNDS See Plans and Pricing
Israel 122546 COMBINATION OF RITONAVIR AND A DRUG METABOLIZED BY CYTOCHROME P450 MONOXYGENASE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for VIEKIRA PAK (COPACKAGED)

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2340029 304 50009-2015 Slovakia See Plans and Pricing PRODUCT NAME: PARITAPREVIR; REGISTRATION NO/DATE: EU/1/14/982/001 20150119
2203431 C02203431/01 Switzerland See Plans and Pricing FORMER OWNER: ABBVIE BAHAMAS LIMITED, BS
2203431 38/2015 Austria See Plans and Pricing PRODUCT NAME: DASABUVIR ODER EIN SALZ DAVON, EINSCHLIESSLICH DASABUVIR-NATRIUM-MONOHYDRAT; REGISTRATION NO/DATE: EU/1/14/983 20150115
2340029 PA2015011,C2340029 Lithuania See Plans and Pricing PRODUCT NAME: PARITAPREVIRAS; REGISTRATION NO/DATE: EU/1/14.982 20150115
2692346 CR 2017 00049 Denmark See Plans and Pricing PRODUCT NAME: PIBRENTASVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/17/1213 20170728
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Colorcon
Merck
Express Scripts
McKesson
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.